Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

TORONTO, ON / ACCESS Newswire / August 19, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, announces a proposed debt settlement pursuant to which the Company intends to issue up to 1,221,516 common shares in the capital of the Company (the "Settlement Shares") at a deemed price of $0.05 per Settlement Share to settle an aggregate of $61,061 in outstanding trade payables owing to two arm's length creditors of the Company (the "Debt Settlement").

Positive DRDC findings support the next phase for bucillamine as Revive plans to pursue government-backed development opportunities, expand intellectual property and evaluate complementary therapeutics TORONTO, ON / ACCESS Newswire / August 19, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today outlined its strategy to build a focused medical-countermeasure portfolio led by bucillamine.

TORONTO, ON / ACCESS Newswire / August 14, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today announced the Board of Directors of Revive has authorized the grant of an aggregate of 15,500,000 incentive stock options to key members of our team, including directors, officers, and consultants.

TORONTO, ON / ACCESS Newswire / August 12, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today announced positive results from a research study conducted by Defence Research and Development Canada - Suffield Research Centre ("DRDC") evaluating bucillamine in an established animal model of nerve-agent exposure.